Linagliptin Farmak

Linagliptin, the active ingredient in Linagliptin Farmak, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control. It works by increasing incretin levels, which enhances insulin secretion in a glucose‑dependent manner while reducing glucagon release.

GNH USA supplies Linagliptin Farmak as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across EU and other markets.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycaemic control as part of a comprehensive diabetes management plan. Adjunct to diet and exercise: used together with lifestyle measures to lower blood glucose levels. Combination therapy: added to metformin or other oral antidiabetics when glycaemic targets are not met. Monotherapy in patients intolerant to other agents: provides glucose‑lowering effect without weight gain.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: abnormal liver function tests or jaundice.

When prescribing linagliptin, clinicians should consider several precautionary measures to ensure patient safety.

Renal function: assess baseline renal function and monitor periodically, although dose adjustment is not required. Hepatic function: evaluate liver enzymes before initiation and during therapy. Pancreatitis risk: advise patients to report persistent abdominal pain or vomiting. Elderly patients: monitor for dizziness and hypoglycaemia when combined with other agents. Hypersensitivity: discontinue if signs of allergic reaction appear. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycaemia; avoid dose escalation. - Rifampin: strong enzyme inducer that may markedly reduce linagliptin exposure. - Strong P‑gp inducers (e.g., carbamazepine): may lower drug levels and diminish efficacy.

Moderate Interactions (Monitor Closely): - Metformin: monitor renal function as combined therapy may affect renal clearance. - ACE inhibitors: watch for additive blood pressure effects. - Diuretics: observe electrolyte balance, especially when combined with other antihyperglycaemic agents.